A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease

NCT00253201 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

636

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease
Dementia

Interventions

DRUG: galantamine hydrobromide

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.